ALX Oncology Holdings Inc., a clinical-stage biotechnology company, has announced the initiation of a Phase 1 clinical trial for ALX2004, an epidermal growth factor receptor (EGFR) antibody-drug conjugate $(ADC)$ aimed at treating EGFR-expressing solid tumors. The trial marks the first in-human study of ALX2004 and involves an open-label, multicenter approach. It includes a Phase 1a dose escalation portion focusing on patients with advanced or metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer. The trial will subsequently proceed to a dose exploration and expansion phase. Initial safety data from the study is expected to be available in the first half of 2026.